Incyte Corporation is trading 4.4% up at $105.67, extending a sharp three-day rebound from below $93 despite broader U.S. indices trading lower.
- The move appears driven by continued momentum and stock-specific dip-buying rather than new fundamental news, as no fresh earnings, FDA decisions, or major analyst calls emerged this morning.
- The stock is modestly outperforming a weak, risk-off market backdrop as it maintains its upward trajectory.